A new HER2 mutation leads to a clinical trial and to a promising diagnostic tool for metastatic breast cancer
Articles / Metastatic breast cancer

A new HER2 mutation leads to a clinical trial and to a promising diagnostic tool for metastatic breast cancer

There is a group of metastatic breast cancers that has the HER2 gene amplified – the cells have many copies of it – which leads to enhanced activity of the product enzyme, a tyrosine kinase. HER2 has been established as a therapeutic target in breast cancer, and breast cancers in which the HER2 gene is … Continue reading